Research brief

BPC-157

Also written as Pentadecapeptide BPC 157, PL 14736

Evidence read from: ClinicalTrials.gov, PubMed, FDA · how we work · Last reviewed 9 August 2026

BPC-157 is the most discussed research peptide of the last decade and one of the least tested in people. Its origin story, its safety record and its oral form all rest on claims that trace back to a single research group and have never been independently confirmed. The first genuine placebo-controlled trial in humans began enrolling in February 2026 and will not report until 2028.

Marketed for

Tendon, ligament, muscle and gut healing; injury recovery.

Evidence reviewed

9 August 2026, against 25 sources

Human evidence

Graded, for members. See the membership

If you read nothing else

• •There is not one randomized controlled trial of BPC-157 in the published literature. A PubMed search for BPC-157 filtered to the Clinical Trial publication type returns zero records.
• •The trials endlessly cited as proof of safety in inflammatory bowel disease were never published as full results in any peer-reviewed journal. The claim circulates as a sentence repeated across review articles by the group that ran them.
• •About 78 percent of the entire BPC-157 literature carries the same two authors. No unaffiliated laboratory has directly replicated the flagship tendon, ligament or muscle findings.
• •There is no human pharmacokinetic data by any route. The FDA says so in its own words. The only human dosing with blood sampling found no peptide in plasma at all.
• •The regulatory position moved twice in 2026 and the evidence base did not move with it. FDA removed BPC-157 from its list of compounding substances that may present significant safety risks in April, its own reviewers recommended against admitting the substance to the compounding list in July, and its advisory committee voted 8 to 6 the same month to recommend admitting it anyway. Nothing in that sequence is a finding about whether the compound works.
• •Nobody has ever published an analysis of what is actually inside a vial sold to a consumer as BPC-157. That absence is itself a finding.

Five of the sources, and what they say

Open any of them. Each is tagged with the kind of evidence it is, because a randomized trial in people and an experiment in cell culture answer very different questions. This brief was written against 25 sources of this kind.

1. 1.Review
   Sikiric P, Petek M, Rucman R, et al. A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. J Physiol Paris. 1993;87(5):313-27. PMID 8298609. Open source
2. 2.Regulatory
   US Food and Drug Administration. BPC-157 briefing document, Pharmacy Compounding Advisory Committee, 23-24 July 2026. Open source
3. 3.Review
   McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Curr Rev Musculoskelet Med. 2025;18(12):611-619. PMID 40789979. Open source
4. 4.Review
   Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025;21(4):485-495. PMID 40756949. Open source
5. 5.Review
   Sikiric P, Seiwerth S, Rucman R, et al. Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157. Curr Pharm Des. 2013;19(1):76-83. PMID 22950504. Open source

Members read on

The grade and the full review are for members

The findings above are free, and so are the sources. Behind this line is our grade for the human evidence on BPC-157, the full review, what we looked for and could not find, and all 25 sources with the kind of evidence each one is.

The grade is our judgment, and the review is the working behind it: what has actually been run in people, what it measured instead, who ran it, who paid for it, and which results were never published at all. Our findings are above and our sources are open, so nothing here asks you to take the reasoning on trust. What a membership buys is where we land, and why.

Nobody who sells peptides pays us anything, and nothing we earn changes what a brief says. Members are the only people paying us, which is the only reason a brief here is free to be unflattering.

$5 a month or $29 a year. Membership opens in waves, so the button takes you to the place where you choose a price and hold a seat. No card is taken today. The peptide tracker stays free for everyone, member or not.